

1 **Full Title: Antiphospholipid antibodies exacerbate damage following oxygen**
2 **deprivation-reperfusion injury in an *in vivo* model for stroke and in *ex vivo* blood**
3 **derived endothelial cells**

4
5 **Short Title:**
6 **Antiphospholipid antibodies in reperfusion injury**

7
8 Charis Pericleous^{1,2*}, Daniel J. Stuckey^{3‡}, Robert T. Maughan^{1‡}, Koralia Paschalaki¹, Lida
9 Kabir¹, Lauren T. Bourke², Rohan Willis⁴, Anisur Rahman², Anna M. Randi¹, Deepa J.
10 Arachchillage^{5,6}, Mark Lythgoe³, Ian P. Giles², Justin C. Mason^{1,6§}, Yiannis Ioannou^{2§}

11
12 ¹National Heart & Lung Institute, Imperial College London, London, UK

13 ²Centre for Rheumatology, University College London, London UK

14 ³Centre for Advanced Biomedical Imaging, University College London, London UK

15 ⁴Rheumatology, University of Texas Medical Branch, Galveston, TX, USA

16 ⁵Department of Immunology & Inflammation, Imperial College London, London UK

17 ⁶Imperial College NHS Trust, London, UK

18
19 ‡contributed equally

20 §joint senior authors

21
22 ***Corresponding author:**

23 Charis Pericleous

24 Imperial College London

25 National Heart & Lung Institute ICTEM L5

26 Du Cane Road, London W12 0NN

27
28 Email: c.pericleous@imperial.ac.uk

29 Tel: + 44 207 594 2728

52 **Abstract**

53

54 **Background:** Prothrombotic antiphospholipid antibodies (aPL) found in patients with
55 antiphospholipid syndrome (APS) are a recognised risk factor for ischemic stroke. However,
56 it is unclear if aPL cause injury post thrombolysis leading to worse outcomes. We investigated
57 whether aPL exacerbate reperfusion injury and sought to translate our findings in endothelial
58 colony forming cells (ECFC) isolated from patients with APS.

59 **Methods:** Transient ischemic stroke was induced in adult rats injected with serum-derived
60 IgG from patients with APS (APS-IgG, containing aPL) or healthy controls (HC-IgG). Infarct
61 size and intracellular signalling processes involved in ischemia-reperfusion injury were
62 determined post reperfusion. *In vitro*, human umbilical vein endothelial cells (HUVEC) treated
63 with IgG, as well as APS and HC ECFC, were exposed to hypoxia (0.1% O₂). Cell death and
64 relevant signalling mechanisms were assessed following reperfusion and compared to
65 matched normoxic cultures.

66 **Results:** *In vivo*, APS-IgG induced >2-fold larger infarcts and lower levels of active
67 phosphorylated Akt, a key pro-survival kinase, compared to HC-IgG. *In vitro*, aPL-mediated
68 cell death and suppression of Akt phosphorylation was confirmed in HUVEC exposed to IgG
69 and hypoxia-reperfusion. Consistent with these findings, higher rates of cell death and
70 reduced Akt phosphorylation following reperfusion were observed in *ex vivo* APS ECFC
71 compared to HC ECFC. Treatment with the immunomodulating agent hydroxychloroquine
72 ameliorated ECFC death and this effect was more pronounced in APS-derived cells.

73 **Conclusion:** Patient-derived IgG aPL exacerbate cell death following reperfusion in a novel
74 *in vivo* stroke model for APS, as well as *in vitro* HUVEC cultures. These observations are
75 mimicked in *ex vivo* APS ECFC. Our findings describe a novel pathogenic role for aPL in
76 mediating tissue injury in addition to their known thrombogenic properties and indicate
77 potential for pharmacological intervention.

78 **Introduction**

79
80 Stroke remains a significant cause of morbidity and mortality worldwide. Ischemic stroke
81 accounts for >80% of cases and 10-15% of those occur in young adults.¹ Approximately 10-
82 20% of patients under 50 years old with stroke have antiphospholipid syndrome (APS), the
83 most common identifiable cause of acquired hypercoagulability in the general population.^{2,3}
84 APS is clinically defined by thrombotic events and/or obstetric complications with persistent
85 presence of circulating antiphospholipid autoantibodies (aPL).⁴ aPL positivity is a strong risk
86 factor for stroke, particularly in young patients and in the absence of classical cardiovascular
87 risk factors (e.g. hyperlipidemia, hypertension, smoking, metabolic disease). Risk of recurrent
88 thrombosis is also elevated in aPL-positive young patients. A prospective study of >1800
89 patients between 18-45 years old and previous ischemic stroke identified aPL as an
90 independent predictor of long-term recurrent vascular events after first stroke using a
91 composite endpoint of stroke, transient ischemic attack, myocardial infarction (MI) or other
92 arterial events.⁵

93
94 Pathogenic aPL are primarily raised against plasma cofactors that bind phospholipids; more
95 recently pathogenic aPL that directly target phospholipids have also been described.⁶ To date
96 the plasma protein beta-2 glycoprotein I (β_2 GPI) has been identified as the most important
97 autoantigen. The ability of β_2 GPI to bind cell membrane receptors and phospholipids
98 facilitates aPL priming of endothelium, platelets, monocytes and neutrophils resulting in a
99 proinflammatory and procoagulant phenotype.⁷ Thrombosis in APS is a 'two-hit' phenomenon:
100 aPL provide the first thrombophilic 'hit' and clotting ensues upon exposure to a second 'hit'
101 such as infection or injury. Endothelial injury is central to APS pathogenesis, and existing
102 animal models convincingly demonstrate the prothrombotic nature of aPL and endothelial
103 involvement in carotid, cardiac, mesenteric and femoral vascular territories.⁸⁻¹⁴

104
105 Restoration of blood flow with thrombolysis is the first-line treatment for occlusive ischemic
106 events. However, organ reperfusion can exacerbate tissue damage. The extent of reperfusion
107 injury is ultimately determined by the complex interplay between intracellular 'live-or-die'
108 signals modulated by the activity of key protein kinases. In cardiac ischemia-reperfusion injury,
109 the role of protein kinase B (PKB/Akt) and p38-mitogen activated protein kinase
110 (MAPK)/extracellular signal-regulated kinase (ERK) signalling are well established and
111 directly relate to myocardial damage.¹⁵ Similarly, these kinases are implicated in brain
112 ischemia-reperfusion injury and neuronal survival.^{16,17} aPL can regulate all three kinases.^{7,18-}
113 ²⁴ We previously demonstrated that aPL engage p38-mitogen activated protein kinase (MAPK)
114 to promote cell death in a model of hypoxia-reperfusion injury *in vitro* using primary rat
115 cardiomyocytes; this mechanism was dependent on the interaction between aPL and the
116 immunodominant region of β_2 GPI.²⁵ *In vivo*, β_2 GPI localizes to the liver and uterus but spreads
117 to the brain when mice are challenged with lipopolysaccharide²⁶ suggesting that β_2 GPI
118 localizes to the brain following a pathogenic insult. Following stroke, β_2 GPI synthesis is
119 upregulated in the liver, localizes to the brain parenchyma and endothelium, and promotes
120 vascular inflammation.²⁷ It is therefore plausible that, following ischemia-reperfusion injury and
121 endothelial blood-brain barrier (BBB) breakdown, aPL entering the brain microcirculation can
122 interact with brain tissue via β_2 GPI.

123
124 It is unclear whether aPL increase stroke severity or impact long-term outcomes; studies in
125 patients are limited but suggest increased stroke severity and risk of post-stroke disability,²⁸
126 cognitive impairment²⁹ and haemorrhagic transformation associated with longer
127 hospitalisation periods and higher mortality.³⁰ We hypothesized that aPL disrupt the fine
128 balance between cell survival and death post ischemia and exacerbate stroke damage during
129 reperfusion by targeting essential survival signalling mechanisms. We employed a well-
130 established rat model of transient middle cerebral artery occlusion (MCAO) to design the first

131 *in vivo* model for stroke in APS and translated our findings in patient endothelial colony forming
132 cells (ECFC), a novel source of patient-derived endothelium isolated from venous blood.³¹
133

134 **Methods**

136 **Patients and healthy donors**

137 All research subjects signed informed consent according to the Declaration of Helsinki and
138 approved by the appropriate local, regional and/or national Ethics board (University College
139 London, Imperial College London, University of Texas Medical Branch).
140

141 A total of 20 patients with APS and 17 healthy controls (HC) were recruited for this study.
142 Polyclonal IgG was isolated from 14 APS and 12 HC; ECFC were isolated from 12 APS and
143 12 HC donors. Samples from 6 patients and 7 HC were used for both IgG and ECFC isolation.
144 Demographics and clinical information are listed in Table 1. Positive aPL status was recorded
145 from clinical records and confirmed for IgG anti-cardiolipin (aCL) and anti- β 2GPI (a β 2GPI)
146 using in-house assays (see Methods: IgG aPL activity).
147

148 **IgG purification**

149 IgG was purified from human serum by protein G chromatography (ThermoFisher Scientific
150 UK). IgG preparations were concentrated and dialyzed in phosphate buffered saline (PBS)
151 and confirmed to be free of endotoxin (<0.1EU/mL at 1mg/mL concentration of IgG) (EndoLisa,
152 Hyglos Germany).
153

154 For *in vivo* experiments, equal amounts of IgG isolated from two APS patients with comparable
155 aPL activity (Table 1) were pooled into a single sample (APS-IgG). A second IgG pool was
156 prepared from four aPL-negative healthy controls (HC-IgG). Both pools were prepared to a
157 concentration of 1mg/mL under sterile conditions. For *in vitro* experiments, IgG samples were
158 tested individually at a concentration of 100 μ g/mL.
159

160 **IgG quantification**

161 Individual and pooled IgG samples were quantified by spectrophotometry and enzyme-linked
162 immunosorbent assay (ELISA).^{13,32} Briefly, 96-well maxisorp plates (Nunc) were coated with
163 an Fc-specific anti-human IgG antibody (Sigma-Merck UK) and blocked to minimize non-
164 specific binding. Serially diluted human IgG was tested in duplicate. Goat anti-human
165 horseradish peroxidase (HRP)-conjugated IgG (Sigma-Merck), tetramethylbenzidine (TMB)
166 substrate and 0.1M sulphuric acid (KPL Diagnostics, Insight Biotechnology UK) were
167 employed and optical density read at 450nm. IgG concentrations were calculated from a
168 standard curve generated by serially diluting commercially sourced IgG from 100ng/mL to
169 3.125ng/mL (Sigma-Merck).
170

171 Human IgG content was also measured in rodent serum (1:400 dilution)^{13,32} and neat brain
172 tissue lysates (prepared as described below). To confirm assay specificity for human IgG,
173 serum and brain lysates from three rats not injected with human IgG or subjected to MCAO
174 were tested. No signal was detected (data not shown).
175

176 **IgG aPL activity**

177 IgG aCL and a β 2GPI activity was measured in purified IgG fractions, human and rat serum
178 using direct ELISA with pre-defined cut offs as previously described.³³ In brief, 96-well plates
179 were coated with bovine cardiolipin (Sigma-Merck) or human β 2GPI (Enzyme Research
180 Laboratories UK). Human serum, rodent serum and purified IgG (serially diluted from
181 500 μ g/mL) were tested as described.^{13,32} Signal detection was performed as per the total
182 human IgG ELISA. aCL activity was defined as IgG phospholipid units (GPLU) using validated
183 calibrators (Louisville aPL Diagnostics, USA; activity range 16-120 GPLU). For a β 2GPI,
184 activity was defined as IgG β 2GPI units (GBU) using in-house calibrators (activity range 3.1-

185 100 GBU). Titres >99th percentile of the activity of n=200 control sera were considered positive
186 (17GPLU; 8GBU).³³ LA testing and interpretation was performed by the clinical laboratory
187 following ISTH guidelines.³⁴

188

189 ***In vivo* studies**

190 Animal studies were approved by the University College London Biological Services Ethical
191 Review Committee and licensed under the UK Home Office regulations and the Guidance for
192 the Operation of Animals (Scientific Procedures) Act 1986 (Home Office, London, United
193 Kingdom). Male Sprague Dawley (SD) rats (Charles River, UK) weighing between 200-220g,
194 receiving a standard diet and water ad libitum were anaesthetized with 2% isoflurane and
195 injected intravenously with 1mg of pooled APS-IgG or HC-IgG (n=5 per group). The trachea
196 and common carotid artery (CCA) were exposed and isolated. Fifteen minutes post IgG
197 injection, a sterile microfilament was introduced into the CCA and positioned to fully occlude
198 the right MCA.^{35,36} After 0.5hr or 1hr ischemia, the microfilament was removed to enable
199 reperfusion. Animals were allowed to recover, provided with soft tissue bedding, unrestricted
200 access to water and food and euthanized 24hr post reperfusion (endpoint).

201

202 Two additional groups of rats (n=6 per group) were injected with 1mg of APS-IgG or HC-IgG
203 but not subjected to MCAO surgical procedures. Animals were maintained for 24hr post
204 injection prior to sacrifice.

205

206 Immediately following sacrifice, blood was collected by cardiac puncture for serum isolation.
207 Selected organs were examined and collected for downstream analysis as described below.
208 A schematic of our model is shown in Supplementary Figure 1B.

209

210 **Infarct size analysis**

211 Brains isolated from rats subjected to MCAO were cut into 1mm slices and stained with
212 tetrazolium chloride (TTC) to discriminate between metabolically active (red) and dead tissue
213 (white). Representative slices from an APS-IgG treated rat are shown in Figure 1C. A total of
214 12-13 slices per animal were digitally analysed by a technician blinded to the treatment groups.
215 The area (mm³) of viable and infarcted regions (Figure 1C, red and white tissue respectively)
216 was measured on both sides of each slice and lesion size calculated as a percentage of total
217 brain area.

218

219 **Endothelial cell culture**

220 Pooled human umbilical vein endothelial cells (HUVEC, Lonza) were cultured in complete
221 endothelial growth medium (EGM2) containing 10% FBS. Experiments were performed at
222 passage 4.

223

224 For ECFC generation, peripheral blood mononuclear cells (PBMC) were isolated from whole
225 blood by gradient centrifugation (Ficoll-Paque Plus GE Healthcare). Counted viable PBMC
226 were resuspended in complete EGM2 supplemented with 20% FBS and seeded at $\geq 0.8 \times 10^6$
227 / cm² in culture vessels pre-coated with Type I rat tail collagen (BD Bioscience). The media
228 was carefully changed two days post-seeding and repeated every 2-3 days. From five days
229 post-seeding, cultures were routinely screened for the appearance of cobblestone cells that
230 formed dense endothelial colonies over time. Cultures were expanded for 6-8 weeks post-
231 PBMC seeding. Our ECFC isolation protocol is summarized in Supplementary Figure 3A.
232 Representative images of an emerging colony, expanded ECFC and expression of canonical
233 endothelial markers detected by immunofluorescence, are shown in Supplementary Figure
234 3B. ECFC were confirmed to be of endothelial but not myeloid lineage by flow cytometry
235 (CD31+/CD144+/CD146+/CD45-/CD14-, Supplementary Figure 3C) and $\geq 98\%$ pure at
236 passage 4. Experiments were performed at passage 4-5.

237

238 **Simulated hypoxia-reperfusion *in vitro***

239 Hypoxia was mimicked by incubating cell cultures in 0.1% O₂/5% CO₂ supplemented with
240 nitrogen (H35 hypoxic workstation, Don Whitley Scientific) for 4hrs followed by reperfusion
241 under standard culture conditions (~20% O₂) for 0.5hr to 24hrs. Endothelial basal medium
242 (EBM2) in the absence of growth factors or FBS was used during hypoxia. Cells were switched
243 back to complete EGM2 during reperfusion. Where indicated, matched normoxic cultures were
244 kept under standard conditions in EGM2 for the duration of each experiment. Endothelial
245 cultures were routinely visualized to confirm confluency and monolayer robustness throughout
246 the outlined experimental conditions and time points. All measurements were performed in ≥
247 2 independent experiments.

248
249 HUVEC were pre-incubated with 100µg/mL purified human IgG for 24hr prior to hypoxia-
250 reperfusion simulation. IgG was retained in the culture medium at all times.

251
252 ECFC were cultured in the absence of exogenous IgG. For targeted experiments with
253 hydroxychloroquine (HCQ, 10µg/mL), ECFC were pre-treated with the drug for 24hr prior to
254 hypoxia-reperfusion simulation. HCQ was retained in the culture medium at all times.

255 256 **Protein extraction**

257 Small brain slices from the posterior part of the brain were collected from all animals (MCAO
258 and no MCAO) and snap frozen in liquid nitrogen. The kidney, liver, spleen, left carotid artery
259 and aorta were also snap frozen. Tissues were ground to a fine powder using a mortar and
260 pestle placed on dry ice. Approximately 150-200µg of ground tissue was mixed with RIPA
261 (ThermoFisher) or cell lysis buffer (Cell Signaling Technologies UK) containing protease and
262 phosphatase inhibitors (Roche) and incubated on ice for 10min. Lysates were passed through
263 a glass homogeniser and incubated on ice for a further 15min, then spun at 17000g for 10min
264 to pellet cell debris. Total protein in collected supernatants was quantified by bicinchoninic
265 acid (BCA) assay (ThermoFisher) and stored at -20°C.

266
267 HUVEC and ECFC were placed on ice and washed twice with HBSS, incubated for 10min
268 with lysis buffer and manually scraped off the culture vessel. Lysates were spun, supernatant
269 collected and quantified as above.

270 271 **Immunoblotting**

272 10µg protein lysate was mixed with loading buffer containing SDS and dithiothreitol (DTT),
273 boiled at 95°C for 5mins, separated by electrophoresis (4-12% Bolt Bis-Tris pre-cast gels,
274 ThermoFisher) and transferred onto polyvinylidene difluoride (PDVF) membrane (GE
275 Healthcare UK). Membranes were incubated with primary antibodies followed by species-
276 specific HRP-conjugated or fluorescently labelled secondary antibodies (Supplementary
277 Table 1). Proteins were visualized by chemiluminescence after substrate addition (ECL, GE
278 Healthcare) or by fluorescence (LICOR Odyssey imaging system). Molecular target levels
279 were normalised by calculating the ratio between phosphorylated and total target protein or
280 phosphorylated protein and housekeeping/loading controls.

281 282 **Immunoprecipitation**

283 100µg tissue lysate in 200µL lysis buffer was mixed with 5µL of Akt antibody and incubated
284 with gentle rocking overnight at 4°C. Then, 20µL of protein G agarose (ThermoFisher) was
285 added for a further 3hr and the mixture centrifuged at 14000g for 30sec. After five washes with
286 cold lysis buffer, the pellet was resuspended in SDS loading buffer and handled as described
287 above.

288 289 **Endothelial cell kinetic apoptosis & necrosis assay**

290 HUVEC or ECFC were seeded at 1x10⁴ per well in 96-well white walled clear bottom culture
291 plates and tested in triplicate under hypoxia-reperfusion and normoxic conditions. Following
292 2hr reperfusion, apoptosis and necrosis was simultaneously measured in hypoxia-reperfusion
293 and matched normoxic plates by luminescence and fluorescence respectively (RealTime-Glo

294 Annexin V Apoptosis and Necrosis Assay, Promega UK). Luminescence and fluorescence
295 measurements were obtained for 24hr post reperfusion and expressed as fold change of
296 apoptosis or necrosis in hypoxia-reperfusion versus matched normoxic cells. Samples were
297 tested in ≥ 2 independent experiments.

298
299 As a positive control for this assay, HUVEC under normoxic conditions were treated for 2hr
300 with 100 μ M hydrogen peroxide (H₂O₂) followed by washout/recovery for 24hr. H₂O₂ induced
301 both necrosis and apoptosis (Supplementary Figure 2A). Results are expressed as fold
302 change of apoptosis/necrosis between H₂O₂ and untreated HUVEC (n=2 individual HUVEC
303 pools).

304 305 **Statistical analysis**

306 Results are presented as (A) Box-and-whisker plots with each data point representing an
307 individual sample. The vertical line inside each plot represents the median value for each data
308 set \pm interquartile range (IQR); or (B) line graphs, each line representing an individual sample.
309 Two-tailed unpaired Mann Whitney were used to compare 2 experimental groups and
310 Kruskal-Wallis followed by Dunn's multiple comparisons tests for >2 groups. Where
311 applicable, paired analysis was performed with equivalent paired non-parametric tests. For
312 correlation analysis, Spearman's tests were applied. Significance in all cases, p<0.05.
313 Experiments with n \leq 3 per group were not statistically analysed.

314 315 **Results**

316 317 **APS-IgG increase brain infarct size**

318 For *in vivo* studies, purified IgG was pooled from 2 patients with APS and 4 HC (Table 1).
319 Patients were triple aPL positive in serological assays (LA, high titre IgG aCL, IgG a β ₂GPI)
320 and all HC were negative. Purified IgG samples were individually tested for aPL activity prior
321 to pooling, confirming high-titre aPL activity in APS-IgG (at 100 μ g/mL, aCL and a β ₂GPI activity
322 was >100 units for both samples)³³ and lack of aPL activity in HC-IgG (tested at up to
323 500 μ g/mL; Supplementary Figure 1A).

324
325 In the first instance, we performed MCAO for 1hr followed by 24hr reperfusion. Brain infarcts
326 in the APS-IgG group tended to be larger than HC-IgG. The border zone, the most peripheral
327 zone of the affected area and with less distinct pallor than the infarcted core, was also
328 extended (Figure 1A). However, three of eight animals injected with APS-IgG (37.5%) died
329 within 2hr reperfusion. Histology performed on two of three deceased rats revealed infarcts
330 >30% of total brain area (Figure 1A, red diamonds). For the remaining five APS-IgG animals
331 that survived 24hr post reperfusion plus the two histologically analysed animals that died, we
332 observed a series of systemic abnormalities during histological analysis. Specifically, we
333 identified brain clots in 4/7 animals; liver clots in 1/7; dark areas across the heart in 5/7; dark
334 areas in the lungs in 1/7; trouble breathing in 1/7; piloerection in 1/7; and viscous blood in 3/7.
335 Only one animal in the HC-IgG group had dark spots on the liver and viscous blood at
336 endpoint.

337
338 The sudden death of a substantial proportion of APS-IgG animals combined with our
339 histological observations suggested that experimental conditions were too harsh in the
340 presence of aPL, and potentially resembled a phenotype closer to the clinical syndrome
341 'catastrophic APS.' This rare form of APS is typified by spontaneous development of multiple
342 microthrombi, consequent multi-organ failure and 40-50% mortality despite aggressive
343 immunosuppression. Therefore, we opted to reduce the duration of MCAO to 0.5hr and
344 maintain reperfusion at 24hr (schematic summary, Supplementary Figure 1B).

345
346 Under these conditions, APS-IgG animals had 2.3-fold larger infarcts compared to HC-IgG
347 [infarcted % of total brain area, median (IQR) 31.3% (28.2-36.6) versus 13.6% (10.2-18.9),

348 p=0.008; n=5 per group) (Figure 1B-C)]. We singularly noted dark areas in the kidney and liver
349 in two animals and a third had viscous blood. No other abnormalities or premature death were
350 seen.

351
352 For comparison, two additional groups of animals received APS-IgG or HC-IgG but were not
353 subjected to MCAO (no-MCAO); endpoint was defined as 24hr post-IgG transfer. In brain
354 lysates prepared from MCAO and no-MCAO groups, human IgG was more abundant in MCAO
355 compared to no-MCAO tissue, confirming BBB breakdown (Figure 1D). Human IgG levels
356 were similar in APS-IgG and HC-IgG MCAO brain lysates suggesting that any downstream
357 differences can be directly attributed to pathogenic aPL found in APS-IgG.

358
359 Similarly, circulating human IgG was detected in both APS-IgG and HC-IgG treated rats.
360 Human IgG levels were higher in MCAO compared to no-MCAO littermates and may point
361 towards IgG retention in the circulation following injury (Figure 1E). In line with this, serum aPL
362 activity was detectable in APS-IgG treated rats 15min post-injection (Figure 1F) and at
363 endpoint (Figure 1G-H). While circulating aCL were equally detectable in both MCAO and no-
364 MCAO APS-IgG littermates (Figure 1G), a β 2GPI levels were pronounced in the APS-IgG
365 MCAO group only (Figure 1H) suggesting greater a β 2GPI retention following injury. All HC-
366 IgG rat sera were aPL negative.

367 368 **APS-IgG inhibit pro-survival Akt following brain ischemia-reperfusion injury**

369
370 Consistent with enhanced infarct size in APS-IgG animals, the apoptotic marker cleaved
371 caspase-3 was elevated in APS-IgG compared to HC-IgG animals following MCAO, and
372 minimal or absent in no-MCAO brain lysates (Figure 1I). We assessed whether aPL disrupts
373 pro-survival mechanisms, key for limiting reperfusion injury and initiating repair.
374 Phosphorylation of the pro-survival kinase Akt (p-Akt) was measured on its two critical
375 activation sites (S473, T308); T308 phosphorylation allows initial Akt activation and S473
376 phosphorylation further enhances its catalytic activity. In the absence of MCAO, p-Akt S473
377 levels were similar in APS-IgG and HC-IgG animals (Figure 2A, Supplementary Figure 1C).
378 Following MCAO and as expected, p-Akt S473 levels were higher in HC-IgG treated animals
379 compared to their no-MCAO littermates, suggesting induction of pro-survival signalling.
380 However, elevated p-Akt following MCAO was not observed in APS-IgG animals. Comparison
381 of APS-IgG and HC-IgG MCAO groups revealed strikingly lower phosphorylation at both S473
382 (Figure 2A, Supplementary Figure 1C) and T308 (Supplementary Figure 1D) in the presence
383 of aPL. Levels of p-Akt S473 negatively correlated with infarct size highlighting the protective
384 role of Akt following ischemia-reperfusion injury ($r = -0.9048$, $p = 0.005$; Supplementary Figure
385 1E). Phosphorylated levels of other key kinases involved in reperfusion signalling were similar
386 between APS-IgG and HC-IgG animals following MCAO (p38, ERK1/2, JNK1/2;
387 Supplementary Figure 1F). Taken together, our observations indicate specific inhibition of p-
388 Akt by aPL following oxygen deprivation-reperfusion.

389
390 Previous studies highlight the ability of IgG aPL to interfere with Akt signalling. Canaud *et al*
391 reported aPL-mediated *induction* of p-Akt contributing to endothelial hyperplasia in APS
392 nephropathy²⁴ while Sacharidou *et al* demonstrated prothrombotic aPL-mediated *inhibition* via
393 protein phosphatase 2A (PP2A),³⁷ one of three molecular Akt inhibitors. We searched for
394 involvement of the molecular Akt inhibitors PP2A, phosphatase and tensin homolog (PTEN)
395 and thioesterase superfamily member 4 (*THEM4*, CTMP) in a limited number of brain lysates
396 from animals subjected to MCAO. Total levels of the PP2A catalytic subunit (PP2AC) and
397 PTEN did not differ between APS-IgG and HC-IgG groups (Figure 2B, left panel). CTMP was
398 not detected. Following targeted Akt immunoprecipitation, evidence favouring PP2A
399 involvement was inconclusive (Figure 2B, right panel and Figure 2C). Instead, an interaction
400 between Akt and PTEN in APS-IgG animals was detected (Figure 2B, right panel and Figure
401 2D). Akt-bound PTEN was in an activated form as shown by its dephosphorylated state (Figure
402 2B, right panel and Figure 2E). Since PTEN degradation following stroke may be

403 neuroprotective,³⁸ its role and potential manipulation in our model may warrant future
404 exploration.

405
406 Next, we studied the catalytic ability of Akt by measuring activation of its downstream
407 substrates in MCAO brain lysates. Phosphorylated levels of the pro-apoptotic BCL2-
408 associated agonist of cell death (p-Bad), which is inhibited by Akt phosphorylation on S136,
409 were reduced in APS-IgG animals (Figure 2F). Consistent with elevated cleaved caspase-3
410 levels (Figure 1H), a process also regulated by Akt, these observations highlight exacerbated
411 pro-death signalling in the presence of aPL.

412
413 Akt supports protein synthesis via phosphorylation of the mammalian target of rapamycin
414 (mTOR) and its downstream effector S6 ribosomal protein (S6RP). Lower p-S6RP levels were
415 detected in the APS-IgG group (Akt target site serine-235/6, Figure 2G). This was an intriguing
416 finding since Canaud *et al* demonstrated elevated p-Akt *and* p-S6RP localized to vascular
417 endothelium in renal biopsies from APS nephropathy patients compared to non-APS disease
418 and healthy controls.²⁴ We probed kidney lysates from our animal model and found that, in
419 stark contrast to the brain, p-Akt kidney levels were higher in APS-IgG than HC-IgG following
420 MCAO (Figure 2H, Supplementary Figure 1G). For comparison, we measured p-Akt levels in
421 the liver and spleen but did not detect any differences suggesting that in our model, aPL
422 specifically modulated p-Akt in the brain and kidney (Supplementary Figure 1H).

423
424 The APS nephropathy study suggested that aPL activate Akt in the absence of other stimuli.²⁴
425 Upon challenge with exogenous vascular endothelial growth factor (VEGF, a potent Akt
426 inducer), aPL were shown to inhibit activation of the vascular homeostatic enzyme endothelial
427 nitric oxide synthase (eNOS), as demonstrated by reduced phosphorylation of the Akt-
428 regulated S1177 eNOS residue.³⁷ We hypothesized that the natural process of Akt induction
429 following ischemia-reperfusion is challenged by aPL and leads to inhibition of p-eNOS, as
430 described in the context of VEGF. We probed brain lysates from our model and noted
431 suppression of p-eNOS in APS-IgG MCAO animals (Figure 2I). In carotid artery specimens
432 collected from the same animals, a similar pattern of p-Akt and p-eNOS inhibition was seen in
433 the APS-IgG group while in the aorta, these molecules were inconsistently affected (Figure
434 2J, p-Akt and Figure 2K, p-eNOS).

435 436 **APS-IgG enhance cell death and inhibit Akt following hypoxia-reperfusion in cultured** 437 **endothelial cells**

438
439 Previous aPL-Akt associated studies focused on endothelium,^{24,37} a major aPL target.⁷ Given
440 the importance of endothelial BBB breakdown in stroke, *in vitro* endothelial models were next
441 employed to confirm our findings. Healthy HUVEC treated with APS-IgG or HC-IgG (24hr)
442 were exposed to hypoxia under nutrient restricting conditions (0.1% O₂, 4hr) followed by
443 reperfusion and nutrient restoration. Cell death was measured in real time for up to 24hr
444 reperfusion and compared to matched cultures kept in normoxic conditions. Sensitivity of the
445 cell death assay was confirmed in HUVEC exposed to H₂O₂ (Supplementary Figure 2A) or
446 hypoxia-reperfusion (Supplementary Figure 2B). Comparison of APS-IgG vs HC-IgG treated
447 HUVEC responses revealed a non-significant trend for elevated apoptosis following 2hr
448 reperfusion (Figure 3A) and significantly elevated necrosis at all time points (Figure 3B),
449 indicating enhanced endothelial cell death in the presence of aPL.

450
451 We sought to establish whether aPL influence endothelial Akt *in vitro*, building on evidence
452 from our *in vivo* observations and from published aPL-endothelial studies.^{24,37} Initially, we
453 tested the same samples used to create pooled IgG for *in vivo* injections (n=2 APS, n=2 HC)
454 and selected phosphorylated targets were measured after 2hr reperfusion. In untreated
455 HUVEC, both p-Akt and p-Bad were elevated following hypoxia-reperfusion compared to
456 normoxia (Supplementary Figure 2C-D). In APS-IgG treated HUVEC, reduced levels of p-Akt,
457 p-Bad and p-eNOS were detected under hypoxia-reperfusion and compared to HC-IgG

458 treated cells (Figure 3C). Reduced p-Akt induction in the presence of aPL, was confirmed in
459 an extended sample set of purified IgG (n=12 APS-IgG, n=10 HC-IgG; Table 1) used to treat
460 matched HUVEC cultures under hypoxia-reperfusion or normoxia (Figure 3D, Supplementary
461 Figure 2E). These results further highlight that aPL disrupts Akt signalling following a context-
462 specific insult, in this case hypoxia-reperfusion injury.

463

464

464 **APS ECFC response to hypoxia/reperfusion mimics *in vivo* observations**

465

466 Next, we employed *ex vivo* ECFC to study the impact of hypoxia-reperfusion injury on APS
467 endothelium (n=12 donors per group; Table 1). ECFC from patients with systemic disease
468 such as APS, are chronically exposed to circulating pathogenic mediators such as
469 autoantibodies and inflammatory cytokines, ultimately leading to a 'primed' phenotype that
470 persists *ex vivo*.^{31,39} Utilising APS ECFC in our study would therefore facilitate extension of
471 our *in vivo* and *in vitro* findings to a biologically relevant source of patient endothelium.

472

473 ECFC generation parameters as outlined by ECFC standardization guidelines⁴⁰ including
474 number of endothelial colonies detected, day of first colony detection and day of first passage
475 from P0 to P1 (defined as days-post PBMC seeding), were similar for APS and HC ECFC
476 (Supplementary Figure 3D) suggesting that any functional or molecular differences detected
477 were not due to initial isolation and growth capacity of patient vs control cells.

478

479 All experiments were performed in parallel matched hypoxia-reperfusion and normoxic
480 cultures. Mirroring the HUVEC-IgG experiments, ECFC were exposed to hypoxia and cell
481 death was tracked in real time for 24hr post reperfusion. Hypoxia-reperfusion promoted cell
482 death in both APS and HC ECFC compared to normoxic cells (Figure 4A-B, Supplementary
483 Figure 4A-B). Both apoptosis (Figure 4A) and necrosis (Figure 4B) were significantly more
484 prominent in APS-ECFC.

485

486 Dysregulation of the p-Akt response following hypoxia-reperfusion was next determined.
487 Induction of p-Akt was observed in both APS and HC ECFC following hypoxia-reperfusion and
488 compared to matched cells kept under normoxia (Supplementary Figure 4C). However, p-Akt
489 levels were robustly lower in APS-ECFC compared to HC-ECFC at both 0.5hr (early) and 2hr
490 (late) post-reperfusion, as well as under normoxic conditions (Figure 4C). Failure to activate
491 Akt resulted in the expected reduction of downstream p-Bad in APS ECFC (Figure 4D,
492 Supplementary Figure 4D). In agreement with the regulatory relationship between Akt and
493 Bad, early p-Akt correlated with late p-Bad (r=0.622, p=0.035; Supplementary Figure 4E).
494 Thus, our *ex vivo* findings in APS and HC ECFC recapitulated our *in vivo* observations and
495 the *in vitro* IgG-HUVEC model.

496

497 **Hydroxychloroquine partially protects against hypoxia-reperfusion induced ECFC 498 death**

499

500 Our group and others reported a protective effect for hydroxychloroquine (HCQ) following
501 brain,⁴¹ heart^{42,43} and kidney⁴⁴ ischemia-reperfusion injury *in vivo* and in cellular models.^{42,44}
502 We determined whether HCQ could reverse ECFC death following hypoxia-reperfusion. Cells
503 were pre-treated with HCQ for 24hr followed by hypoxia-reperfusion or normoxic culture as
504 described. Under normoxic conditions, HCQ had a variable effect on apoptosis and necrosis
505 (Supplementary Figure 5A-B). Following reperfusion, HCQ suppressed apoptosis (Figure 5A)
506 and necrosis (Figure 5B) in both APS and HC ECFC but yielded a stronger protective effect
507 upon APS ECFC death.

508

509 We measured p-Akt and p-Bad levels in a small sample set (n=3 per group); p-Akt levels were
510 similar between untreated and HCQ-treated lysates (data not shown) but p-Bad levels
511 appeared to rise following HCQ treatment and hypoxia-reperfusion (Figure 5C, Supplementary

512 Figure 5C). Taken together, our results suggest that HCQ limits cell death during reperfusion
513 in both APS and non-APS cellular sources but its beneficial effects may be enhanced in APS.

514

515 In this study, ECFC from thrombotic APS patients with or without a previous history of
516 cardiovascular events (CVE vs no-CVE) were used. Comparison of ECFC responses from
517 these two APS subgroups showed equal susceptibility to hypoxia-reperfusion induced cell
518 death (Supplementary Figure 5D). However, *in vitro* treatment with HCQ conferred greater
519 protection in ECFC from no-CVE compared to CVE donors (Figure 5D). Similarly, ECFC
520 responses were compared between patients receiving HCQ compared to those not receiving
521 HCQ at the time of ECFC isolation (HCQ vs no-HCQ). No differences in the level of cell death
522 (Supplementary Figure 5E) or response to *in vitro* HCQ treatment was observed
523 (Supplementary Figure 5F).

524

525 **Discussion**

526

527 To our knowledge, we present the first *in vivo* model for aPL-mediated cell death following
528 ischemia-reperfusion injury and identify repression of Akt activity as a critical underlying
529 mechanism. We confirm elevated cell death and reduced p-Akt *in vitro* in HUVEC stimulated
530 with exogenous aPL and subjected to hypoxia-reperfusion. Excitingly, use of *ex vivo* APS
531 ECFC fully recapitulated our *in vivo* observations thus directly extending our findings to a
532 patient-relevant source of endothelium.

533

534 Stroke is the most frequent primary arterial thrombotic event in APS and the most frequent
535 recurrent thrombotic event overall (venous and arterial combined).⁴⁵⁻⁴⁷ While the relationship
536 between aPL and stroke is well-established, few studies have compared stroke severity and
537 long-term outcomes between APS and non-APS stroke patients, a particularly challenging
538 task as APS strokes occur in younger patients. A study in patients <54 years old identified a
539 correlation between aPL titres, stroke severity on admission and three-month outcomes.²⁸
540 Another study found that cognitive impairment was more common in APS patients compared
541 to age-, gender- and cardiovascular risk factor-matched controls; within one year of follow-up,
542 progression of cognitive impairment occurred in ~21% of APS patients (13/60), 12 of whom
543 had suffered stroke.²⁹ Higher risk of haemorrhagic transformation post APS-associated stroke
544 regardless of thrombolytic therapy was also reported; APS patients spent longer periods in
545 hospital and had a greater risk of mortality despite being significantly younger compared to
546 non-APS stroke patients.³⁰

547

548 Here, we investigated the impact of aPL in a vascular event setting such as stroke, focusing
549 on the critical period following clot dissolution and brain reperfusion by employing a non-
550 thrombotic outcome. Our study highlights an additional pathogenic effect of aPL that goes
551 beyond lowering the threshold for arterial thrombosis and describes a mechanism for
552 enhanced tissue injury during the reperfusion phase, which may account for the worse
553 prognosis proposed in APS-associated stroke. Patients may benefit from close monitoring,
554 particularly if thrombolysis is given, and incorporating readouts for disability and cognitive
555 impairment during long-term follow up.

556

557 We propose that aPL, free to enter the brain following BBB breakdown, impact Akt-mediated
558 homeostatic mechanisms critical to cell survival during reperfusion. Analysis of limited material
559 from our *in vivo* model may indicate a role for the tumour suppressor PTEN in aPL-mediated
560 Akt inhibition. This was a surprising finding as PTEN acts upstream of Akt to prevent activation
561 of phosphoinositide 3-kinase (PI3K)-Akt signalling and may indicate the presence of an
562 inhibitory complex composed of Akt, PTEN and other PI3K signalling components recruited to
563 sites near the plasma membrane.

564

565 Another unexpected finding was that, following stroke, renal p-Akt levels were elevated in
566 APS-IgG compared to HC-IgG animals, an observation that agrees with an elegant study for

567 APS nephropathy.²⁴ In the absence of stroke, p-Akt levels did not differ between APS-IgG and
568 HC-IgG kidney or brain. We speculate that, similar to the ‘two-hit’ model for thrombotic APS,
569 the presence of circulating aPL combined with the haemodynamic impact of MCA occlusion
570 influences the renal system in our model and drives renal Akt activation.

571
572 Both the APS nephropathy study and a second *in vivo* thrombosis model study implicate
573 dysregulation of Akt and its signalling mediators in endothelium, but in opposing ways –
574 suggesting activation²⁴ and inhibition³⁷ respectively. A key difference between these two
575 studies was the use of exogenous VEGF (a potent Akt inducer) in the latter,³⁷ suggesting that
576 aPL may prevent Akt activation following biomechanical challenge. Harnessing this
577 information, we sought to understand the premise of aPL-mediated Akt dysregulation in the
578 presence of an Akt-activating stimulus such as hypoxia-reperfusion. We focused on
579 endothelium, initially showing reduced p-eNOS levels (a downstream Akt target) in brain and
580 carotid artery specimens from APS-IgG animals. A series of *in vitro* experiments corroborated
581 our *in vivo* findings, whereby aPL repressed Akt activation following *in vitro* hypoxia-
582 reperfusion. We utilized two sources of endothelial cells: HUVEC treated with APS-IgG (the
583 most common *in vitro* model for aPL-endothelial studies) and ECFC isolated from patients.

584
585 ECFC, considered to originate from true circulating endothelial ‘progenitors’, are capable of
586 clonal expansion and vascular repair, and appear to be ‘biologically primed’ even after long
587 term *in vitro* culture. This precious source of patient endothelium has offered mechanistic
588 insight into endothelial dysfunction across a range of diseases,³¹ including rheumatoid arthritis
589 where ECFC were shown to be hyperproliferative, proangiogenic and sensitized to TNF α
590 stimulation.³⁹ Here, we utilise APS ECFC for the first time to demonstrate that both functional
591 (cell death) and molecular (Akt) outcomes are negatively impacted under hypoxia-reperfusion,
592 mirroring our *in vivo* observations and underlining the utility of ECFC for the exploration of
593 endothelial dysfunction in APS.

594
595 Our study has some limitations. Our model follows a standard approach of passive transfer of
596 aPL *in vivo* to study APS pathogenesis (‘acute’ APS models). ‘Chronic’ APS models involving
597 immunisation with cardiolipin or β 2GPI, are less common but mimic observations from acute
598 models. We used a small number of animals for our *in vivo* model and a moderate number of
599 patients (purified IgG and ECFC) to confirm our findings. *In vivo* experiments employed pooled
600 IgG isolated from two APS and four HC donors. For comparison, our previous studies^{9,13,21}
601 and those by other groups^{11,12,48} also tested a small number of individual APS-IgG or HC-IgG
602 samples in animal models, ranging from 1-6 samples per group. We previously used pooled
603 HC-IgG *in vivo*^{9,13} and pooled APS-IgG and HC-IgG *in vitro* with downstream individual sample
604 validation.^{22,49} Another limitation is that we did not explore reversal of the Akt response with
605 commercially available pan-Akt activators as they are unlikely to be employed in real world
606 clinical practice.

607
608 Despite these limitations, we demonstrate consistency across our findings and present novel
609 *in vivo* and *ex vivo* ECFC-based models for oxygen deprivation-reperfusion injury in APS.
610 Future work will aim to establish how aPL-mediated functional and molecular disturbances
611 can be therapeutically reversed. We previously reported on the pro-survival effect of HCQ in
612 an *in vivo* cardiac ischemia-reperfusion model and in cardiomyocytes *in vitro*.⁴² This effect was
613 mediated by ERK and not Akt, but serves as an example of repurposing or reconsidering the
614 benefits of pre-existing drugs already used in autoimmune disease management. Here, using
615 blood-derived ECFC we provide proof-of-principle that HCQ may offer protection against cell
616 death following hypoxia-reperfusion, an effect that is more pronounced in APS compared to
617 HC ECFC. Incorporating HCQ as an adjunct immunomodulatory treatment in APS
618 management is increasingly implemented, and may provide similar benefits to those seen in
619 systemic lupus erythematosus and rheumatoid arthritis where HCQ is proposed to reduce
620 cardiovascular risk.⁵⁰

621 In conclusion, we translate biological evidence generated from a novel *in vivo* APS stroke
622 model to *in vitro* studies with aPL-treated HUVEC and finally, to APS-derived *ex vivo* EC. We
623 identify an intervenable pathobiological process independent of thrombosis that may inform
624 clinical management of patients with aPL and stroke. Further research is required to establish
625 whether aPL-mediated Akt disturbances can be manipulated therapeutically and the efficacy
626 of immunomodulation towards thrombotic and non-thrombotic pathogenesis in APS.

627

628 **Acknowledgments**

629 This manuscript is dedicated to Professor Justin Mason (Imperial College London) and
630 Professor Silvia Pierangeli (University of Texas Medical Branch) who passed away
631 prematurely. We are sincerely grateful to Mrs Valerie Taylor (University College London) for
632 sharing her expertise and supporting the *in vivo* part of this study. Infrastructure support for
633 this research was provided by the NIHR Imperial Biomedical Research Centre (BRC).

634

635 **Sources of Funding**

636 C.P is supported by Versus Arthritis (21223) and the Imperial College-Wellcome Trust
637 Institutional Strategic Support Fund. D.J.S. was supported by British Heart Foundation
638 Intermediate and Senior Basic Science Research Fellowships (FS/15/33/31608,
639 FS/SBSRF/21/31020), the BHF Centre for Regenerative Medicine (RM/17/1/33377), the MRC
640 (MR/R026416/1) and the Wellcome Trust (212937/Z/18/Z). D.J.A is funded by the MRC
641 (MR/V037633/1). This work was partly funded by the Rosetrees Trust (C.P, I.P.G).

642

643 **Disclosures**

644 C.P, A.R, I.P.G and Y.I are co-inventors on a novel drug for APS (US20160287718A). There
645 are no other relevant disclosures.

646

647 **References**

- 648 1. Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: a
649 systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*
650 2019;18(5):439-58.
- 651 2. Sciascia S, Sanna G, Khamashta MA, et al. The estimated frequency of antiphospholipid
652 antibodies in young adults with cerebrovascular events: a systematic review. *Ann Rheum Dis*
653 2015;74(11):2028-33.
- 654 3. George MG. Risk Factors for Ischemic Stroke in Younger Adults: A Focused Update. *Stroke*
655 2020;51(3):729-35.
- 656 4. Barbhaiya M, Zully S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome
657 classification criteria. *Ann Rheum Dis* 2023;82(10):1258-70.
- 658 5. Pezzini A, Grassi M, Lodigiani C, et al. Predictors of long-term recurrent vascular events
659 after ischemic stroke at young age: the Italian Project on Stroke in Young Adults. *Circulation*
660 2014;129(16):1668-76.
- 661 6. Muller-Calleja N, Kohler A, Siebald B, et al. Cofactor-independent antiphospholipid
662 antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications
663 for the antiphospholipid syndrome. *Thromb Haemost* 2015;113(5):1071-83.
- 664 7. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome:
665 understanding the antibodies. *Nat Rev Rheumatol* 2011;7(6):330-9.
- 666 8. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of
667 murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human
668 immunoglobulin G antiphospholipid antibodies. *Circulation* 1996;94(7):1746-51.
- 669 9. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN.
670 Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells
671 in vitro and in vivo. *Circulation* 1999;99(15):1997-2002.
- 672 10. Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-
673 dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the
674 hamster. *Blood* 2003;101(1):157-62.

- 675 11. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-
676 glycoprotein I is complement dependent and requires a priming factor. *Blood*
677 2005;106(7):2340-6.
- 678 12. Arad A, Proulle V, Furie RA, Furie BC, Furie B. beta(2)-Glycoprotein-1 autoantibodies from
679 patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation
680 in a mouse model. *Blood* 2011;117(12):3453-9.
- 681 13. Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. Proof-of-concept study
682 demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of
683 beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis.
684 *Rheumatology (Oxford)* 2015;54(4):722-7.
- 685 14. Meng H, Yalavarthi S, Kanthi Y, et al. In Vivo Role of Neutrophil Extracellular Traps in
686 Antiphospholipid Antibody-Mediated Venous Thrombosis. *Arthritis Rheumatol*
687 2017;69(3):655-67.
- 688 15. Armstrong SC. Protein kinase activation and myocardial ischemia/reperfusion injury.
689 *Cardiovasc Res* 2004;61(3):427-36.
- 690 16. Zhao H, Sapolsky RM, Steinberg GK. Phosphoinositide-3-kinase/akt survival signal
691 pathways are implicated in neuronal survival after stroke. *Mol Neurobiol* 2006;34(3):249-70.
- 692 17. Sun J, Nan G. The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a
693 Discovery Target in Stroke. *J Mol Neurosci* 2016;59(1):90-8.
- 694 18. Aronovich R, Gurwitz D, Kloog Y, Chapman J. Antiphospholipid antibodies, thrombin and
695 LPS activate brain endothelial cells and Ras-dependent pathways through distinct
696 mechanisms. *Immunobiology* 2005;210(10):781-8.
- 697 19. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement
698 of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid
699 antibodies. *Arthritis Rheum* 2005;52(5):1545-54.
- 700 20. Lopez-Pedraza C, Buendia P, Cuadrado MJ, et al. Antiphospholipid antibodies from
701 patients with the antiphospholipid syndrome induce monocyte tissue factor expression through
702 the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein
703 kinase pathway, and of the MEK-1/ERK pathway. *Arthritis Rheum* 2006;54(1):301-11.
- 704 21. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated
705 protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell
706 activation. *J Thromb Haemost* 2007;5(9):1828-34.
- 707 22. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from
708 patients with different clinical types of the antiphospholipid syndrome on monocyte signaling
709 pathways. *J Immunol* 2010;184(12):6622-8.
- 710 23. Zhou H, Chen D, Xie H, et al. Activation of MAPKs in the anti-beta2GPI/beta2GPI-induced
711 tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. *Thromb Res*
712 2012;130(4):e229-35.
- 713 24. Canaud G, Bienaime F, Tabarin F, et al. Inhibition of the mTORC pathway in the
714 antiphospholipid syndrome. *N Engl J Med* 2014;371(4):303-12.
- 715 25. Bourke LT, McDonnell T, McCormick J, et al. Antiphospholipid antibodies enhance rat
716 neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38
717 MAPK. *Cell Death Dis* 2017;8(1):e2549.
- 718 26. Agostinis C, Biffi S, Garrovo C, et al. In vivo distribution of beta2 glycoprotein I under
719 various pathophysiologic conditions. *Blood* 2011;118(15):4231-8.
- 720 27. Grossi C, Artusi C, Meroni P, et al. beta2 glycoprotein I participates in phagocytosis of
721 apoptotic neurons and in vascular injury in experimental brain stroke. *J Cereb Blood Flow*
722 *Metab* 2021;41(8):2038-53.
- 723 28. Rodriguez-Sanz A, Martinez-Sanchez P, Prefasi D, et al. Antiphospholipid antibodies
724 correlate with stroke severity and outcome in patients with antiphospholipid syndrome.
725 *Autoimmunity* 2015;48(5):275-81.
- 726 29. Medina G, Cime-Ake E, Bonilla-Vazquez R, et al. Disability and cognitive impairment are
727 interdependent in primary antiphospholipid syndrome. *Lupus* 2022;31(9):1104-13.

- 728 30. Mehta T, Hussain M, Sheth K, Ding Y, McCullough LD. Risk of hemorrhagic transformation
729 after ischemic stroke in patients with antiphospholipid antibody syndrome. *Neurol Res*
730 2017;39(6):477-83.
- 731 31. Paschalaki KE, Randi AM. Recent Advances in Endothelial Colony Forming Cells Toward
732 Their Use in Clinical Translation. *Front Med (Lausanne)* 2018;5:295.
- 733 32. Giles I, Pericleous C, Liu X, et al. Thrombin binding predicts the effects of sequence
734 changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. *J*
735 *Immunol* 2009;182(8):4836-43.
- 736 33. Pericleous C, Ferreira I, Borghi O, et al. Measuring IgA Anti-beta2-Glycoprotein I and
737 IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the
738 Antiphospholipid Syndrome. *PLoS One* 2016;11(6):e0156407.
- 739 34. Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and
740 Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the
741 International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus
742 anticoagulant detection and interpretation. *J Thromb Haemost* 2020;18(11):2828-39.
- 743 35. Badin RA, Modo M, Cheetham M, et al. Protective effect of post-ischaemic viral delivery
744 of heat shock proteins in vivo. *J Cereb Blood Flow Metab* 2009;29(2):254-63.
- 745 36. Panizzo RA, Gadian DG, Sowden JC, Wells JA, Lythgoe MF, Ferretti P. Monitoring
746 ferumoxide-labelled neural progenitor cells and lesion evolution by magnetic resonance
747 imaging in a model of cell transplantation in cerebral ischaemia. *F1000Res* 2013;2:252.
- 748 37. Sacharidou A, Chambliss KL, Ulrich V, et al. Antiphospholipid antibodies induce
749 thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium.
750 *Blood* 2018;131(19):2097-110.
- 751 38. Li W, Huang R, Chen Z, Yan LJ, Simpkins JW, Yang SH. PTEN degradation after ischemic
752 stroke: a double-edged sword. *Neuroscience* 2014;274:153-61.
- 753 39. Leblond A, Pezet S, Cauvet A, et al. Implication of the deacetylase sirtuin-1 on synovial
754 angiogenesis and persistence of experimental arthritis. *Ann Rheum Dis* 2020;79(7):891-900.
- 755 40. Smadja DM, Melero-Martin JM, Eikenboom J, Bowman M, Sabatier F, Randi AM.
756 Standardization of methods to quantify and culture endothelial colony-forming cells derived
757 from peripheral blood: Position paper from the International Society on Thrombosis and
758 Haemostasis SSC. *J Thromb Haemost* 2019;17(7):1190-94.
- 759 41. Babataheri S, Malekinejad H, Mosarrezai A, Soraya H. Pre-treatment or post-treatment
760 with hydroxychloroquine demonstrates neuroprotective effects in cerebral
761 ischemia/reperfusion. *Fundam Clin Pharmacol* 2022
- 762 42. Bourke L, McCormick J, Taylor V, et al. Hydroxychloroquine Protects against Cardiac
763 Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation. *PLoS*
764 *One* 2015;10(12):e0143771.
- 765 43. Marsh KM, Rastogi R, Zhang A, Wu D, Kron IL, Yang Z. Hydroxychloroquine Attenuates
766 Myocardial Ischemic and Post-Ischemic Reperfusion Injury by Inhibiting the Toll-Like Receptor
767 9 - Type I Interferon Pathway. *Cardiol Cardiovasc Med* 2022;6(4):416-23.
- 768 44. Tang TT, Lv LL, Pan MM, et al. Hydroxychloroquine attenuates renal ischemia/reperfusion
769 injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. *Cell Death Dis*
770 2018;9(3):351.
- 771 45. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic
772 manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis*
773 *Rheum* 2002;46(4):1019-27.
- 774 46. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the
775 antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000
776 patients. *Ann Rheum Dis* 2009;68(9):1428-32.
- 777 47. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid
778 syndrome during a 10-year period: a multicentre prospective study of 1000 patients. *Ann*
779 *Rheum Dis* 2015;74(6):1011-8.
- 780 48. Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for
781 enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.
782 *Blood* 2014;124(4):611-22.

- 783 49. Ripoll VM, Lambrianides A, Pierangeli SS, et al. Changes in regulation of human monocyte
784 proteins in response to IgG from patients with antiphospholipid syndrome. *Blood*
785 2014;124(25):3808-16.
- 786 50. Arachchilage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an Immunomodulatory
787 and Antithrombotic Treatment in Antiphospholipid Syndrome. *Int J Mol Sci* 2023;24(2)
788

789 **Tables**

790

791

Table 1: Demographics and clinical characteristics of sampled cohort.

	IgG- <i>in vivo</i>		IgG-HUVEC		ECFC	
	APS (n=2)	HC (n=4)	APS (n=14)	HC (n=12)	APS (n=12)	HC (n=12)
Age, yrs [Median (Range)]	35.5 (34-37)	30.5 (29-37)	51.0 (34-68)	45.5 (29-61)	59 (25-81)	41.5 (28-61)
Female	2 (100%)	4 (100%)	10 (71%)	10 (83%)	8 (67%)	8 (67%)
Ethnicity*	2W	4W	12W, 1A, 1O	12W	8W, 1A, 1Ar, 1O	10W, 1A, 1B
Clinical history[†] (%)						
Transient ischemic attack	-		1 (7%)		3 (25%)	
Stroke	1 (50%)		10 (71%)		6 (50%)	
Myocardial Infarction	-		2 (14%)		1 (8%)	
Other Arterial Thrombosis	-		2 (14%)		3 (25%)	
Deep Vein Thrombosis	-		3 (21%)		4 (33%)	
Pulmonary Embolism	-		2 (14%)		2 (17%)	
Other Venous Thrombosis	-		1 (7%)		3 (25%)	
Pregnancy morbidity [‡]	1 (50%)		3 (30%)		1 (13%)	
Catastrophic APS	1 (50%)		1 (7%)		-	
Thrombocytopenia	-		1 (7%)		1 (8%)	
SLE-APS [§]	1 (50%)		3 (21%)		-	
aPL serology (%)						
Lupus anticoagulant	2 (100%)		11 (79%)		10 (83%)	
IgG anticardiolipin [#]	2 (100%)		13 (93%)		7 (58%)	
IgG anti- β_2 GPI [#]	2 (100%)		10 (71%)		7 (58%)	
Triple positive	2 (100%)		11 (79%)		5 (42%)	
Treatment (%)						
Warfarin	2 (100%)		12 (86%)		10 (83%)	
Anti-platelet (including aspirin)	-		5 (36%)		8 (67%)	
Hydroxychloroquine	-		6 (43%)		7 (58%)	
ACEi/ARBs, Ca ²⁺ /beta-blockers**	-		4 (29%)		7 (58%)	
Statins	-		2 (14%)		6 (50%)	

792 * W, White; A, Asian; Ar, Arab; B, Black; O, any other ethnic group

793 † Multiple events for some patients

794 ‡ Percentage of female patients with pregnancy morbidity

795 §SLE, systemic lupus erythematosus (secondary APS). No incidence of other rheumatic
796 diseases.

797 #aPL titres >20GPLU for IgG anti-cardiolipin, >8GBU for IgG anti- β_2 GPI tested in-house
 798 **ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers;
 799 Ca²⁺, calcium channel blockers

800
 801

Supplementary Table 1. List of antibodies.

	Target Species	Host	Dilution	Supplier	Catalogue number
Immunoblot, primary antibody					
Cleaved caspase 3	Human/Rodent	Rabbit	1:1000	Cell Signaling Technology (CST)	
p-Akt S473	Human/Rodent	Rabbit	1:1000	CST	4070
p-Akt T308	Human/Rodent	Rabbit	1:1000	CST	13038
p-Bad S136	Human/Rodent	Rabbit	1:1000	CST	4366/5286
p-eNOS S1177	Human/Bovine/Pig	Rabbit	1:1000	CST	9571
p-S6RP	Human/Rodent	Rabbit	1:5000	CST	4858
Akt	Human/Rodent	Rabbit	1:5000	CST	4685
Akt	Human/Rodent	Mouse	1:5000	CST	2920
β -actin	Human/Rodent	Mouse	1:10000	CST	3700
Bad	Human/Rodent	Rabbit	1:1000	CST	9292
GAPDH	Human/Rodent	Rabbit	1:10000	CST	2118
PP2AC	Human/Rodent	Rabbit	1:1000	CST	2038
PTEN	Human/Rodent	Rabbit	1:1000	CST	9188
np-PTEN	Human/Rodent	Rabbit	1:1000	CST	7960
S6RP	Human/Rodent	Rabbit	1:5000	CST	2217
vinculin	Human/Rodent	Rabbit	1:10000	CST	13901
Immunoprecipitation, capture antibody					
Akt	Human	Rabbit	1:40	CST	4685
Immunoblot, secondary/detection antibody					
Anti-rabbit IgG, horseradish peroxidase	Rabbit	Swine	1:5000	Dako	P039901
Anti-mouse IgG, horseradish peroxidase	Mouse	Goat	1:5000	Dako	P044701
Anti-rabbit IgG, DyLight™ 800-4x PEG	Rabbit	Goat	1:5000	ThermoFisher	SA5-35571
Anti-mouse IgG, AF680	Mouse	Goat	1:10000	ThermoFisher	A32729
Anti-rabbit IgG, conformation specific	Rabbit	Mouse	1:2000	CST	5127
ECFC purity, flow cytometry					
CD144 PE	Human	Mouse	10 μ L	EBioscience	12-1449-82
CD146 BV421	Human	Mouse	5 μ L	Biolegend	361004
CD31 FITC	Human	Mouse	5 μ L	Biolegend	303104
CD45 BV510	Human	Mouse	5 μ L	Biolegend	368526
CD14 APC	Human	Mouse	5 μ L	Biolegend	301808
Zombie NIR™ Fixable Viability Dye	-	-	1:375	Biolegend	423106

802

803 **Figure Legends**

804
805 **Figure 1. aPL enhance brain injury following ischemia-reperfusion *in vivo*.** Rats injected
806 with 1mg human IgG were subjected to transient middle cerebral artery occlusion (MCAO)
807 followed by reperfusion (n=5-8 APS-IgG; n=5-6 HC-IgG). An additional litter of rats were
808 injected with APS-IgG or HC-IgG but not subjected to MCAO (no-MCAO, n=6 per group). **(A)**
809 MCAO was performed for 1hr and reperfusion for 24hr (n=8 APS-IgG; n=6 HC-IgG). A total of
810 3/8 APS mice died before endpoint (2/3 with completed histology are marked as red
811 diamonds). Analysis was performed after excluding animals that died pre-endpoint. **(B)** MCAO
812 was reduced to 0.5hr followed by reperfusion for 24hr (n=5 per group). Rats administered
813 APS-IgG had significantly larger infarcts at endpoint. **(C)** Example image of brain slices
814 stained with tetrazolium chloride (TTC) to discriminate between metabolically active (red) and
815 dead tissue (white). **(D-E)** Higher levels of human IgG were detected in **(D)** brain lysates and
816 **(E)** serum from MCAO compared to no-MCAO littermates. **(F)** Fifteen minutes post IgG
817 injection and prior to MCAO, rat serum was sampled for IgG aPL activity. Both aCL and anti-
818 β 2GPI were detected. **(G-H)** At endpoint, APS-IgG MCAO rat sera were **(G)** aCL and **(H)** anti-
819 β 2GPI positive. aCL were also detected in APS-IgG no-MCAO littermates. aPL were
820 undetectable in HC-IgG rats. **(I)** Activation/cleavage of caspase-3 was evident in MCAO brain
821 tissue and was higher in the APS-IgG group (n=3 per group). Normalised to GAPDH. *p<0.05;
822 **p<0.01; ***p<0.001; ****p<0.0001; ns, non-significant.

823
824 **Figure 2. aPL dysregulate the pro-survival kinase Akt.** **(A)** Following ischemia-reperfusion
825 injury, HC-IgG animals demonstrated increased phosphorylation of Akt (p-Akt S473) in the
826 brain. In comparison, p-Akt was lower in APS-IgG animals (n=4 MCAO, n=6 no-MCAO per
827 IgG group). **(B-E)** Levels of natural Akt inhibitors PP2A(C, catalytic subunit), PTEN and active
828 PTEN (non-phosphorylated, np-PTEN) were unaltered in the two MCAO groups. Whole
829 lysates **(B, left panel)** or Akt-immunoprecipitated lysates **(B, right panel)** were blotted for **(C)**
830 PP2AC, **(D)** PTEN and **(E)** np-PTEN demonstrating that Akt is bound to active PTEN
831 exclusively in the APS group (n=2 per group). **(F-G)** Analysis of downstream Akt signalling in
832 MCAO brain revealed lower levels of **(F)** p-Bad S136 and **(G)** p-S6RP S235/6 in the APS
833 group. **(H)** Higher p-Akt levels were detected in matched MCAO kidney lysates from APS-IgG
834 compared to HC-IgG animals. **(I)** Additional Akt signalling analysis identified lower p-eNOS
835 S1177 levels in brain lysates of APS-IgG compared to HC-IgG animals (n=4 per group). **(J)** p-
836 Akt and **(K)** p-eNOS were lower in APS-IgG carotid artery but not aortic lysates (n=3 per
837 group). For panels A, H representative blots are shown for n=3 animals per MCAO and no-
838 MCAO conditions. Complete blots for all individual lysates tested are provided in
839 Supplementary Figure 1C (brain) and 1G (kidney). Results are normalised as follows: p-Akt,
840 p-Bad, p-S6 to total Akt, Bad, S6 respectively; PP2AC, PTEN, np-PTEN to co-
841 immunoprecipitated total Akt; p-eNOS to vinculin. *p<0.05; **p<0.01; ***p<0.001;
842 ****p<0.0001; ns, non-significant.

843
844 **Figure 3. aPL promote endothelial cell death and repress Akt activation following**
845 **hypoxia-reperfusion injury *in vitro*.** HUVEC were incubated with 100 μ g/mL human IgG for
846 4hr under hypoxic conditions followed by reperfusion for up to 24hr. Matched cells were
847 treated with IgG and kept under normoxic conditions. **(A-B)** Cell death is expressed as fold
848 change between 2hr, 3hr and 24hr reperfusion vs matched normoxic cultures. Higher rates of
849 **(A)** apoptosis and **(B)** necrosis were observed in APS-IgG compared to HC-IgG treated
850 HUVEC following hypoxia-reperfusion (n=7 per group). **(C)** After 2hr reperfusion, cells were
851 harvested for protein analysis. Treatment with APS-IgG resulted in lower p-Akt S473, p-Bad
852 S136 and p-eNOS S1177 levels compared to HC-IgG (n=2 per group). Results are normalised
853 to loading controls: p-Akt/p-Bad to β -actin and p-eNOS to vinculin. **(D)** Extended IgG
854 experiments revealed reduction of p-Akt following reperfusion. Representative immunoblots
855 for two APS-IgG and two HC-IgG treated cultures under hypoxia-reperfusion (R) or normoxia
856 (N), and untreated cells (media alone, M). Immunoblots for the remaining IgG samples tested

857 are provided in Supplementary Figure 2E. Results are shown as fold change of p-Akt levels
858 (normalised to β -actin) at 2hr reperfusion vs normoxia (n=12 APS-IgG, n=10 HC-IgG).
859 *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, non-significant.

860
861 **Figure 4. Exacerbated cell death and reduced p-Akt in APS ECFC following hypoxia-**
862 **reperfusion.** Primary ECFC were subjected to hypoxia-reperfusion or normoxia. **(A-B)** Cell
863 death is expressed as fold change between 2hr, 3hr and 24hr reperfusion vs matched
864 normoxic cultures. Higher rates of **(A)** apoptosis and **(B)** necrosis were observed in APS
865 compared to HC ECFC following hypoxia-reperfusion (n=10 per group). Luminescence
866 (apoptosis) and fluorescence (necrosis) traces are provided in Supplementary Figure 4A-B.
867 **(C)** Following 0.5hr and 2hr reperfusion, p-Akt levels were lower in APS (n=7) compared to
868 HC ECFC (n=5). Left panel shows p-Akt normalised to β -actin for 0.5hr, 2hr reperfusion (0.5R,
869 2R) and normoxia (N). Right panel shows fold change of normalised p-Akt between culture
870 conditions. **(D)** Similarly, p-Bad levels were lower in APS compared to HC ECFC. Comparative
871 responses in two untreated HUVEC pools (HUV1, HUV2) are shown for both p-Akt (C) and p-
872 Bad (D); see quantification in Supplementary Figures C-D. Yellow circles, HC; blue circles,
873 APS (n=10 per group). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, non-significant.

874
875 **Figure 5. HCQ protects against hypoxia-reperfusion ECFC death *in vitro*.** **(A-B)** ECFC
876 were pre-treated with 10 μ g/mL hydroxychloroquine (HCQ) for 24hr followed by hypoxia-
877 reperfusion or kept under normoxic conditions. Cell death is expressed as fold change
878 between HCQ-treated and untreated cultures. At 2hr and 3hr post reperfusion, HCQ
879 suppressed **(A)** apoptosis and **(B)** necrosis in APS and a proportion of HC ECFC. This
880 protective effect was more prominent in APS ECFC (n=10 per group). **(C)** HCQ promotes
881 elevated p-Bad levels post-reperfusion in both HC and APS ECFC (n=3 per group). **(D)**
882 Separating APS ECFC donors into those with previous cardiovascular events (CVE, n=6) vs
883 those without (no-CVE, n=4) revealed greater protection from hypoxia-reperfusion induced
884 cell death in the no-CVE group. Results are expressed as fold change of cell death in HCQ-
885 treated vs untreated ECFC. In the absence of HCQ treatment, no obvious difference between
886 cell death rates was observed in CVE vs no-CVE groups (Supplementary Figure 5E). *p<0.05;
887 **p<0.01; ***p<0.001; ****p<0.0001; ns, non-significant.

888
889 **Supplementary Figure 1:**
890 **(A)** Purified APS- and HC-IgG used in the *in vivo* model was tested for aCL and ab2GPI activity
891 at up to 500ug/mL. ELISA results are shown as net optical density units (OD450nm). Using
892 in-house calibrators with pre-defined activity units,³³ both APS-IgG preparations were strongly
893 positive (activity units provided for 100ug/mL). HC-IgG were negative (n=2 APS, n=4 HC).
894 **(B)** Schematic of APS *in vivo* stroke model procedures.
895 **(C)** p-Akt S473 blots for individual brain lysates (n=4 per MCAO group, n=6 per no-MCAO
896 group). Normalised to total Akt. Quantification is shown in Figure 2A.
897 **(D)** p-Akt T308 levels in MCAO rat brain revealed lower levels in APS compared to HC animals
898 (n=4 per group). Normalised to total Akt. Results are shown as median \pm interquartile range.
899 **(E)** p-Akt levels negatively correlate with infarct size (n=4 per group). *p<0.05.
900 **(F)** p38, ERK1/2 (p44/p42) and JNK1/2 (p54/p46) in MCAO rat brain were similar in APS and
901 HC animals (n=4 per group). Normalised to total p38, ERK1/2, JNK1/2 respectively. Results
902 are shown as median \pm interquartile range.
903 **(G)** p-Akt S473 blots for individual kidney lysates (n=5 per APS MCAO, n=4 HC MCAO, n=6
904 APS and HC no-MCAO). Normalised to total Akt. Quantification is shown in Figure 2H.
905 **(H)** p-Akt S473 was assessed in the liver and spleen of MCAO animals with no apparent
906 differences observed (all n=5 except HC spleen, n=4). Normalised to total Akt. Results are
907 shown as median \pm interquartile range.

908
909 **Supplementary Figure 2:**
910 **(A)** As a positive control for the real-time apoptosis/necrosis assay, HUVEC under normoxic
911 conditions were treated for 2hr with 100 μ M H₂O₂ followed by washout/recovery for 24hr. H₂O₂

912 induced both necrosis and apoptosis. Results are shown at 2hr, 3hr and 24hr post-H₂O₂
913 removal and expressed as fold change of apoptosis/necrosis between H₂O₂ and untreated
914 HUVEC (n=2 individual HUVEC pools).

915 **(B)** Enhanced cell death in HUVEC subjected to simulated hypoxia-reperfusion *in vitro*, shown
916 at 2hr, 3hr and 24hr post reperfusion. Results are expressed as fold change of
917 apoptosis/necrosis between matched reperfused and normoxic cultures.

918 **(C)** Levels of p-Akt in HUVEC tested at 0.5hr, 2hr reperfusion (0.5R, 2R) and normoxia (N). p-
919 Akt is higher following hypoxia/reperfusion compared to normoxia. Normalised to β-actin.

920 **(D)** Levels of p-Bad in HUVEC tested at 0.5hr, 2hr reperfusion (0.5R, 2R) and normoxia (N).
921 p-Bad is higher following hypoxia-reperfusion compared to normoxia. Normalised to β-actin.

922 **(E)** p-Akt S473 and β-actin blots for individual APS-IgG and HC-IgG treated HUVEC cultures
923 (n=10 APS-IgG, n=8 HC-IgG shown here). M=media alone, untreated. Lysates were collected
924 at 2hr reperfusion (R) or under normoxia (N). Blots from two additional IgG samples per group
925 and total quantification is shown in Figure 3D.

926

927 **Supplementary Figure 3:**

928 **(A)** Schematic of ECFC isolation. PBMC are plated on collagen coated cell culture vessels
929 and grown in endothelial growth medium-2 (EGM2) supplemented with 20% FBS. Endothelial
930 colonies usually appear within 7-21 days post PBMC seeding and passaged further once well
931 established.

932 **(B)** (i) ECFC colony detected at day 10 post PBMC isolation (left image) and (ii) established
933 ECFC at passage 4 (4x magnification). Representative immunofluorescence images of ECFC
934 at passage 4, stained for canonical endothelial markers (iii) CD144; (iv) von Willebrand factor
935 (vWF); and (v) CD31.

936 **(C)** Flow cytometry gating strategy to characterize endothelial identity of ECFC at passage 4.
937 (i) Forward/side scatter (FS/SS) gating on all cells. (ii) Doublets are excluded to capture only
938 single cells. (iii) Dead cells stained with Zombie dye are excluded. (iv-v) ECFC are
939 CD31/CD144/CD146 positive and (vi) CD45/CD14 negative.

940 **(D)** ECFC generation parameters as recommended by international standardisation
941 guidelines for ECFC isolation.⁴⁰ (i) Colony count: total number of colonies detected,
942 normalised to number of PBMC seeded (x10⁷). (ii) First colony detected: expressed in number
943 of days post PBMC seeding. (iii) First passage: number of days post PBMC seeding where
944 ECFC colonies were passaged from P0 to P1. Results are shown as median ± interquartile
945 range. No significant differences were found.

946

947 **Supplementary Figure 4:**

948 **(A-B)** Representative (A) luminescence (apoptosis) and (B) fluorescence (necrosis) traces for
949 APS and HC ECFC measured at 2hr, 3hr and 24hr reperfusion or normoxia (n=5 per group).
950 The average of n=3 replicate wells per sample per condition is plotted.

951 **(C)** Levels of p-Akt in (i) HC ECFC and (ii) APS ECFC tested at 0.5hr, 2hr reperfusion (0.5R,
952 2R) and normoxia (N). Normalised to β-actin. *p<0.05; ns, non-significant.

953 **(D)** Levels of p-Bad in (i) HC ECFC and (ii) APS ECFC tested at 0.5hr, 2hr reperfusion (0.5R,
954 2R) and normoxia (N). Normalised to β-actin. *p<0.05; ns, non-significant.

955 **(E)** p-Akt levels at 0.5hr (x-axis) correlate with p-Bad levels at 2hr reperfusion (y-axis).

956

957 **Supplementary Figure 5:**

958 **(A-B)** Variable effect of hydroxychloroquine (HCQ) on (A) apoptosis and (B) necrosis in ECFC
959 cultured under normoxic conditions.

960 **(C)** p-Bad levels in HC and APS ECFC with or without HCQ treatment under (i) normoxia and
961 following (ii) 0.5hr or (iii) 2hr reperfusion.

962 **(D)** Comparison of cell death responses in ECFC from APS donors with a previous history of
963 cardiovascular events (CVE) vs those without (no-CVE).

964 **(E)** Comparison of cell death responses in ECFC from APS donors who received HCQ
965 compared to those not receiving HCQ at the time of ECFC isolation.

966 **(F)** Comparison of cell death responses following exogenous HCQ treatment, between ECFC
967 from APS donors who were on HCQ compared to those not on HCQ at the time of ECFC
968 isolation. **(D-F)** are expressed as fold change of cell death rates under hypoxia-reperfusion
969 (H/R) vs normoxia.


Figure 1


Figure 2


Figure 3




Figure 4





Figure 5




Supplementary Figure 1




Supplementary Figure 2



Supplementary Figure 3



Supplementary Figure 4



Supplementary Figure 5

